Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4555341
Max Phase: Preclinical
Molecular Formula: C85H130N14O27
Molecular Weight: 1780.05
Molecule Type: Unknown
Associated Items:
ID: ALA4555341
Max Phase: Preclinical
Molecular Formula: C85H130N14O27
Molecular Weight: 1780.05
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](CNC(=O)CCCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C85H130N14O27/c1-3-5-30-60(79(115)91-53-71(103)93-64(48-57-51-89-59-32-25-24-29-58(57)59)81(117)96-61(31-6-4-2)80(116)98-66(50-77(112)113)83(119)97-63(78(86)114)47-56-27-20-19-21-28-56)95-84(120)67(52-90-68(100)34-26-36-75(108)109)99-82(118)65(49-76(110)111)94-73(105)55-126-46-44-124-42-40-88-72(104)54-125-45-43-123-41-39-87-69(101)38-37-62(85(121)122)92-70(102)33-22-17-15-13-11-9-7-8-10-12-14-16-18-23-35-74(106)107/h19-21,24-25,27-29,32,51,60-67,89H,3-18,22-23,26,30-31,33-50,52-55H2,1-2H3,(H2,86,114)(H,87,101)(H,88,104)(H,90,100)(H,91,115)(H,92,102)(H,93,103)(H,94,105)(H,95,120)(H,96,117)(H,97,119)(H,98,116)(H,99,118)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,121,122)/t60-,61-,62-,63-,64-,65-,66-,67-/m0/s1
Standard InChI Key: VMFFXQXFIYFZKK-OMBHGISSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1780.05 | Molecular Weight (Monoisotopic): 1778.9230 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):